Cognitive & Neuropeptides · Source-reviewed dossier
Dermorphin
Source-Reviewed Research Dossier
Dermorphin is a D-alanine-containing heptapeptide originally identified in frog skin and studied as a potent μ-opioid-receptor agonist. Published work is mainly receptor pharmacology, analogue design and animal analgesia research.
Compound overview
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
- Product type
- Peptide research compound
- Catalog family
- Dermorphin
- Research category
- Cognitive & Neuropeptides
- Catalog CAS RN
- 77614-16-5
- Catalog molecular formula
- C40H50N8O10
- Catalog molecular weight
- 802.88 g/mol
- Catalog sequence
- Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2
- Evidence status
- Receptor and animal analgesia research; no approved human product
- Intended use
- Research, development and manufacturing use only
Literature reference parameters
- Compound or material class
- Frog-skin-derived μ-opioid peptideCatalog-family identity
- Evidence scope
- Receptor and animal analgesia research; no approved human productDo not generalize beyond the cited model
- Source review
- Primary or authoritative records linked belowChecked 2026-09-01
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
How Dermorphin is studied
A target-to-pathway view grounded in the linked research records.
Reported research findings
What published studies report about Dermorphin
Reported outcomes are paired with their experimental model and evidence boundary.
Dermorphin analogues show strong μ-opioid activity
A review summarized sequences, receptor pharmacology and biological activity across the dermorphin peptide family.
Family-level potency data do not define human safety.
Read the primary studyShort dermorphin analogues were studied for prolonged analgesia
A review described tetrapeptide analogues with potent, long-lasting analgesic activity in experimental systems.
Analogue findings are sequence-specific and predominantly preclinical.
Read the primary studyCatalog options
Variant specifications
Pack-level catalog data; lot-level controls remain document-specific.
Specification & documents for DR5
Product specification
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Lot documentation
Request by lot: CoA, HPLC purity and MS identity
Quality documentation
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Interpret the documents, not just the headline number.
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Research context
Published studies and regulatory records, not customer testimonials or usage guidance.
Dermorphin analogues show strong μ-opioid activity
Family-level potency data do not define human safety.
View primary recordShort dermorphin analogues were studied for prolonged analgesia
Analogue findings are sequence-specific and predominantly preclinical.
View primary recordCurated references
Third-party publications selected for direct relevance.
-
01
Peptide-family review
The dermorphin peptide family
Review. 1996. PMID 8981054.
-
02
Analogue review
Dermorphin tetrapeptide analogs as potent and long-lasting analgesics
Review. 2011. PMID 21126548.
Dermorphin questions
Concise answers for researchers comparing identity, evidence and catalog variants.
What is Dermorphin?
Dermorphin is a D-alanine-containing heptapeptide originally identified in frog skin and studied as a potent μ-opioid-receptor agonist. Published work is mainly receptor pharmacology, analogue design and animal analgesia research.
What evidence is available for Dermorphin?
The literature is preclinical and review-based, without an approved dermorphin medicine.
Does the cited research validate this catalog material?
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
Which quality documents can be requested?
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
How should Dermorphin be stored?
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge tools
Continue with structured evidence
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Ready to request a quote?
Selected: DR5 · 5 mg × 10 vials